Your browser doesn't support javascript.
loading
Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment.
Cherney, David Z I; Ferrannini, Ele; Umpierrez, Guillermo E; Peters, Anne L; Rosenstock, Julio; Carroll, Amy K; Lapuerta, Pablo; Banks, Phillip; Agarwal, Rajiv.
Affiliation
  • Cherney DZI; University of Toronto, Toronto, Ontario, Canada.
  • Ferrannini E; CNR Institute of Clinical Physiology, Pisa, Italy.
  • Umpierrez GE; Emory University, Atlanta, Georgia, USA.
  • Peters AL; Keck School of Medicine of the University of Southern California, Los Angeles, California, USA.
  • Rosenstock J; Dallas Diabetes Research Center at Medical City, Dallas, Texas, USA.
  • Carroll AK; Lexicon Pharmaceuticals, Inc., The Woodlands, Texas, USA.
  • Lapuerta P; Lexicon Pharmaceuticals, Inc., The Woodlands, Texas, USA.
  • Banks P; Lexicon Pharmaceuticals, Inc., The Woodlands, Texas, USA.
  • Agarwal R; Indiana University School of Medicine, Indianapolis, Indiana, USA.
Diabetes Obes Metab ; 23(12): 2632-2642, 2021 12.
Article in En | MEDLINE | ID: mdl-34338408
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Diabetes Mellitus, Type 1 / Diabetes Mellitus, Type 2 Type of study: Clinical_trials Limits: Humans Language: En Journal: Diabetes Obes Metab Journal subject: ENDOCRINOLOGIA / METABOLISMO Year: 2021 Type: Article Affiliation country: Canada
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Diabetes Mellitus, Type 1 / Diabetes Mellitus, Type 2 Type of study: Clinical_trials Limits: Humans Language: En Journal: Diabetes Obes Metab Journal subject: ENDOCRINOLOGIA / METABOLISMO Year: 2021 Type: Article Affiliation country: Canada